Global Perspectives

The first part of the 2021 CPhI Annual Report has been published and predicts a strong outlook for CDMOs over the next few years.

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

With the first announced drug shortage tied to the coronavirus outbreak, FDA emphasizes urgency for monitoring drug supply chain.

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

FDA’s approval rate slowed, but the US agency is still ahead of its international counterparts in green-lighting new drugs for market.

Antimicrobial resistance is now the third leading cause of death in the US. As developers continue to leave an unprofitable market, legislation and new reimbursement models propose to stimulate development of new antibiotics.

Researchers in China are playing a role in advancing gene therapy development.

At INTERPHEX 2019, CEO Richard Johnson highlighted the importance of PDA’s new Asian business unit and outlined the organization’s plans. Data integrity guidance for manufacturing and quality systems will be published by the end of the year, as efforts move into big data and artificial intelligence.

The US and pharmerging markets will drive growth in drug spending; number of approvals to increase.

New analysis from the OECD highlights that spending just a couple of dollars per person could help prevent deaths from antimicrobial resistance.

CPhI Korea to feature zone for finished dosage formulation drug products.

WuXi STA supported the development of hepatitis drug through marketing authorization holder pilot program.

Intelligent manufacturing and environmental policies are key trends at P-MEC 2018.

The India Expo Mart in Delhi will host CPhI and P-MEC India with expected attendance of 50,000.

World Health Organization’s Ebola ring vaccination uses Merck & Co.’s investigational rVSV-ZEBOV vaccine to protect high-risk communities in the Democratic Republic of the Congo from Ebola.

Internationalization and regulatory reform are driving growth and investment China.

Brexit-related challenges cast shadows on prospects for the European bio/pharma market in 2018, but optimism may let some sun shine through.

The entities announced that they will partner to improve access to cancer treatments and diagnostics in Ethiopia, Uganda, and Tanzania.

A mutual recognition agreement to accept inspection data from eight EU regulatory authorities may reduce inspection burdens at global drug facilities.

FDA and manufacturers strive to prevent drug shortages from Hurricane Maria.

Reeling from financial and tropical storms, Puerto Rico needs stable industry for recovery.

The program aims to make biosimilars for the treatment of cancer more widely available in middle- and low-income countries.

New study shows China biopharma companies face staffing shortages.

Pharmaceutical Technology spoke with Tommy Fanning, head of biopharmaceuticals for IDA Ireland, to get a perspective on how Brexit may affect the pharmaceutical industry.

US and Chinese pharmacopeial standards groups commit to collaboration on standards for drug safety.

Immuno-oncology drugs are demonstrating patient benefits, but growing resistance to the high cost has implications for patients, market access, and manufacturers.

Aging populations and increased access to healthcare translates into opportunities for biopharmaceutical companies.

The author provides an overview of the key aspects of the current Canadian pharmaceutical market.

Cambridge Consultants engaged in a workshop-style dialogue with a cross section of senior personnel from both Indian and multinational pharma companies to debate whether emerging markets are an opportunity to drive sustainable growth. Conclusions from the workshop are presented in this article.